Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus

what is the clinical relevance?

Steven Tong, Luke Chen, Vance Fowler Jr

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Staphylococcus aureus is a human commensal that can also cause a broad spectrum of clinical disease. Factors associated with clinical disease are myriad and dynamic and include pathogen virulence, antimicrobial resistance, and host susceptibility. Additionally, infection control measures aimed at the environmental niches of S. aureus and therapeutic advances continue to impact upon the incidence and outcomes of staphylococcal infections. This review article focuses on the clinical relevance of advances in our understanding of staphylococcal colonization, virulence, host susceptibility, and therapeutics. Over the past decade key developments have arisen. First, rates of nosocomial methicillin-resistant S. aureus (MRSA) infections have significantly declined in many countries. Second, we have made great strides in our understanding of the molecular pathogenesis of S. aureus in general and community-associated MRSA in particular. Third, host risk factors for invasive staphylococcal infections, such as advancing age, increasing numbers of invasive medical interventions, and a growing proportion of patients with healthcare contact, remain dynamic. Finally, several new antimicrobial agents active against MRSA have become available for clinical use. Humans and S. aureus co-exist, and the dynamic interface between host, pathogen, and our attempts to influence these interactions will continue to rapidly change. Although progress has been made in the past decade, we are likely to face further surprises such as the recent waves of community-associated MRSA.
    Original languageEnglish
    Pages (from-to)185-200
    Number of pages16
    JournalSeminars in Immunopathology
    Volume34
    Issue number2
    DOIs
    Publication statusPublished - 2011

    Fingerprint

    Methicillin-Resistant Staphylococcus aureus
    Virulence
    Staphylococcus aureus
    Staphylococcal Infections
    Therapeutics
    Infection Control
    Anti-Infective Agents
    Delivery of Health Care
    Incidence
    Infection

    Cite this

    @article{3f81d37868cb41c7aa1a09fd26ba8879,
    title = "Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?",
    abstract = "Staphylococcus aureus is a human commensal that can also cause a broad spectrum of clinical disease. Factors associated with clinical disease are myriad and dynamic and include pathogen virulence, antimicrobial resistance, and host susceptibility. Additionally, infection control measures aimed at the environmental niches of S. aureus and therapeutic advances continue to impact upon the incidence and outcomes of staphylococcal infections. This review article focuses on the clinical relevance of advances in our understanding of staphylococcal colonization, virulence, host susceptibility, and therapeutics. Over the past decade key developments have arisen. First, rates of nosocomial methicillin-resistant S. aureus (MRSA) infections have significantly declined in many countries. Second, we have made great strides in our understanding of the molecular pathogenesis of S. aureus in general and community-associated MRSA in particular. Third, host risk factors for invasive staphylococcal infections, such as advancing age, increasing numbers of invasive medical interventions, and a growing proportion of patients with healthcare contact, remain dynamic. Finally, several new antimicrobial agents active against MRSA have become available for clinical use. Humans and S. aureus co-exist, and the dynamic interface between host, pathogen, and our attempts to influence these interactions will continue to rapidly change. Although progress has been made in the past decade, we are likely to face further surprises such as the recent waves of community-associated MRSA.",
    keywords = "altastaph, antiinfective agent, aurograb, aztreonam, bacterial protein, bacterial vaccine, beta lactam antibiotic, ceftaroline, daptomycin, immunoglobulin, inh a21, linezolid, monoclonal antibody, pagibaximab, Panton Valentine leukocidin, penicillin G, polypeptide antibiotic agent, Staphylococcus vaccine, staphyloxanthin, telavancin, tigecycline, unclassified drug, v 710, vancomycin, veronate, abdominal infection, antibiotic resistance, bacteremia, bacterial colonization, bacterial virulence, clinical feature, community acquired pneumonia, comorbidity, disease association, disorders of mitochondrial functions, drug blood level, drug cost, drug distribution, drug efficacy, drug safety, endocarditis, gastrointestinal symptom, genotype, hospital acquired pneumonia, host susceptibility, human, immune deficiency, infection risk, kidney failure, lactic acidosis, methicillin resistant Staphylococcus aureus infection, nausea, neuropathy, nonhuman, pneumonia, priority journal, review, skin infection, skin protection, staphylococcal skin infection, Staphylococcus aureus, Staphylococcus infection, thrombocytopenia, unspecified side effect, vomiting, Disease Susceptibility, Environment, Host-Pathogen Interactions, Humans, Methicillin-Resistant Staphylococcus aureus, Risk Factors, Staphylococcal Infections",
    author = "Steven Tong and Luke Chen and {Fowler Jr}, Vance",
    year = "2011",
    doi = "10.1007/s00281-011-0300-x",
    language = "English",
    volume = "34",
    pages = "185--200",
    journal = "Seminars in Immunopathology",
    issn = "1863-2297",
    publisher = "Springer",
    number = "2",

    }

    Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus : what is the clinical relevance? / Tong, Steven; Chen, Luke; Fowler Jr, Vance.

    In: Seminars in Immunopathology, Vol. 34, No. 2, 2011, p. 185-200.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus

    T2 - what is the clinical relevance?

    AU - Tong, Steven

    AU - Chen, Luke

    AU - Fowler Jr, Vance

    PY - 2011

    Y1 - 2011

    N2 - Staphylococcus aureus is a human commensal that can also cause a broad spectrum of clinical disease. Factors associated with clinical disease are myriad and dynamic and include pathogen virulence, antimicrobial resistance, and host susceptibility. Additionally, infection control measures aimed at the environmental niches of S. aureus and therapeutic advances continue to impact upon the incidence and outcomes of staphylococcal infections. This review article focuses on the clinical relevance of advances in our understanding of staphylococcal colonization, virulence, host susceptibility, and therapeutics. Over the past decade key developments have arisen. First, rates of nosocomial methicillin-resistant S. aureus (MRSA) infections have significantly declined in many countries. Second, we have made great strides in our understanding of the molecular pathogenesis of S. aureus in general and community-associated MRSA in particular. Third, host risk factors for invasive staphylococcal infections, such as advancing age, increasing numbers of invasive medical interventions, and a growing proportion of patients with healthcare contact, remain dynamic. Finally, several new antimicrobial agents active against MRSA have become available for clinical use. Humans and S. aureus co-exist, and the dynamic interface between host, pathogen, and our attempts to influence these interactions will continue to rapidly change. Although progress has been made in the past decade, we are likely to face further surprises such as the recent waves of community-associated MRSA.

    AB - Staphylococcus aureus is a human commensal that can also cause a broad spectrum of clinical disease. Factors associated with clinical disease are myriad and dynamic and include pathogen virulence, antimicrobial resistance, and host susceptibility. Additionally, infection control measures aimed at the environmental niches of S. aureus and therapeutic advances continue to impact upon the incidence and outcomes of staphylococcal infections. This review article focuses on the clinical relevance of advances in our understanding of staphylococcal colonization, virulence, host susceptibility, and therapeutics. Over the past decade key developments have arisen. First, rates of nosocomial methicillin-resistant S. aureus (MRSA) infections have significantly declined in many countries. Second, we have made great strides in our understanding of the molecular pathogenesis of S. aureus in general and community-associated MRSA in particular. Third, host risk factors for invasive staphylococcal infections, such as advancing age, increasing numbers of invasive medical interventions, and a growing proportion of patients with healthcare contact, remain dynamic. Finally, several new antimicrobial agents active against MRSA have become available for clinical use. Humans and S. aureus co-exist, and the dynamic interface between host, pathogen, and our attempts to influence these interactions will continue to rapidly change. Although progress has been made in the past decade, we are likely to face further surprises such as the recent waves of community-associated MRSA.

    KW - altastaph

    KW - antiinfective agent

    KW - aurograb

    KW - aztreonam

    KW - bacterial protein

    KW - bacterial vaccine

    KW - beta lactam antibiotic

    KW - ceftaroline

    KW - daptomycin

    KW - immunoglobulin

    KW - inh a21

    KW - linezolid

    KW - monoclonal antibody

    KW - pagibaximab

    KW - Panton Valentine leukocidin

    KW - penicillin G

    KW - polypeptide antibiotic agent

    KW - Staphylococcus vaccine

    KW - staphyloxanthin

    KW - telavancin

    KW - tigecycline

    KW - unclassified drug

    KW - v 710

    KW - vancomycin

    KW - veronate

    KW - abdominal infection

    KW - antibiotic resistance

    KW - bacteremia

    KW - bacterial colonization

    KW - bacterial virulence

    KW - clinical feature

    KW - community acquired pneumonia

    KW - comorbidity

    KW - disease association

    KW - disorders of mitochondrial functions

    KW - drug blood level

    KW - drug cost

    KW - drug distribution

    KW - drug efficacy

    KW - drug safety

    KW - endocarditis

    KW - gastrointestinal symptom

    KW - genotype

    KW - hospital acquired pneumonia

    KW - host susceptibility

    KW - human

    KW - immune deficiency

    KW - infection risk

    KW - kidney failure

    KW - lactic acidosis

    KW - methicillin resistant Staphylococcus aureus infection

    KW - nausea

    KW - neuropathy

    KW - nonhuman

    KW - pneumonia

    KW - priority journal

    KW - review

    KW - skin infection

    KW - skin protection

    KW - staphylococcal skin infection

    KW - Staphylococcus aureus

    KW - Staphylococcus infection

    KW - thrombocytopenia

    KW - unspecified side effect

    KW - vomiting

    KW - Disease Susceptibility

    KW - Environment

    KW - Host-Pathogen Interactions

    KW - Humans

    KW - Methicillin-Resistant Staphylococcus aureus

    KW - Risk Factors

    KW - Staphylococcal Infections

    UR - http://www.scopus.com/inward/record.url?scp=84859845115&partnerID=8YFLogxK

    U2 - 10.1007/s00281-011-0300-x

    DO - 10.1007/s00281-011-0300-x

    M3 - Article

    VL - 34

    SP - 185

    EP - 200

    JO - Seminars in Immunopathology

    JF - Seminars in Immunopathology

    SN - 1863-2297

    IS - 2

    ER -